Calcium dobesilate may alleviate diabetes‑induced endothelial dysfunction and inflammation

Zhou,Yijun; Yuan,Jiangzi; Qi,Chaojun; Shao,Xinghua; Mou,Shan; Ni,Zhaohui

doi:10.3892/mmr.2017.7740

Calcium dobesilate may alleviate diabetes‑induced endothelial dysfunction and inflammation

Authors:
- Yijun Zhou
- Jiangzi Yuan
- Chaojun Qi
- Xinghua Shao
- Shan Mou
- Zhaohui Ni
View Affiliations

Affiliations: Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P.R. China
Published online on: October 9, 2017 https://doi.org/10.3892/mmr.2017.7740
Pages: 8635-8642
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic kidney disease (DKD) is a leading cause of end‑stage renal disease. However, the pathogenesis of DKD remains unclear, and no effective treatments for the disease are available. Thus, there is an urgent need to elucidate the pathogenic mechanisms of DKD and to develop more effective therapies for this disease. Human umbilical vein endothelial cells (HUVECs) were cultured using different D‑glucose concentrations to determine the effect of high glucose (HG) on the cells. Alternatively, HUVECs were incubated with 100 µmol/l calcium dobesilate (CaD) to detect its effects. The authors subsequently measured HUVEC proliferation via cell counting kit‑8 assays. In addition, HUVEC angiogenesis was investigated via migration assays and fluorescein isothiocyanate (FITC)‑labelled bovine serum albumin (BSA) permeability assays. The content or distribution of markers of endothelial dysfunction [vascular endothelial growth factor (VEGF), VEGF receptor (R) and endocan) or inflammation [intercellular adhesion molecule (ICAM)‑1, monocyte chemotactic protein (MCP)‑1 and pentraxin‑related protein (PTX3)] was evaluated via reverse transcription‑quantitative polymerase chain reaction and western blotting. HG treatment induced increased in VEGF, VEGFR, endocan, ICAM‑1, MCP‑1 and PTX3 mRNA and protein expression in HUVECs. HG treatment for 24 to 48 h increased cell proliferation in a time‑dependent manner, but the cell proliferation rate was decreased at 72 h of HG treatment. Conversely, CaD inhibited abnormal cell proliferation. HG treatment also significantly enhanced HVUEC migration compared to the control treatment. In contrast, CaD treatment partially inhibited HUVEC migration compared to HG exposure. HG‑treated HUVECs exhibited increased FITC‑BSA permeability compared to control cells cultured in medium alone; however, CaD application prevented the HG‑induced increase in FITC‑BSA permeability and suppressed HG‑induced overexpression of endothelial markers (VEGF, VEGFR‑2, endocan) and inflammation markers (ICAM‑1, MCP‑1, PTX3) in HUVECs. CaD has angioprotective properties and protects endothelial cells partly by ameliorating HG‑induced inflammation. The current results demonstrated the potential applicability of CaD to the treatment of diabetic nephropathy, particularly during the early stages of this disease.

View Figures

View References

1	International Diabetes Federation, . Diabetes Atlas (7th edition). 2015.https://www.diabetesatlas.org
2	Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, et al: Diabetic kidney disease: A report from an ADA Consensus Conference. Am J Kidney Dis. 64:510–533. 2014. View Article : Google Scholar : PubMed/NCBI
3	Fu J, Lee K, Chuang PY, Liu Z and He JC: Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol. 308:F287–F297. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cheng H and Harris RC: Renal endothelial dysfunction in diabetic nephropathy. Cardiovasc Haematol Disord Drug Targets. 14:22–33. 2014. View Article : Google Scholar
5	Navarro-González JF, Mora-Fernández C, de Fuentes M Muros and García-Pérez J: Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 7:327–340. 2011. View Article : Google Scholar : PubMed/NCBI
6	Galkina E and Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol. 17:368–377. 2006. View Article : Google Scholar : PubMed/NCBI
7	Sugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kushiro M, Shikata Y, Miyatake N, Miyasaka M and Makino H: Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: Glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes. 46:2075–2081. 1997. View Article : Google Scholar : PubMed/NCBI
8	Seron D, Cameron JS and Haskard DO: Expression of VCAM-1 in the normal and diseased kidney. Nephrol Dial Transplant. 6:917–922. 1991. View Article : Google Scholar : PubMed/NCBI
9	Tejerina T and Ruiz E: Calcium dobesilate: Pharmacology and future approaches. Gen Pharmacol. 31:357–360. 1998. View Article : Google Scholar : PubMed/NCBI
10	Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh-Jafari H and Ghabili K: Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis. 19:62–68. 2013.PubMed/NCBI
11	Rabe E, Jaeger KA, Bulitta M and Pannier F: Calcium dobesilate in patients suffering from chronic venous insufficiency: A double-blind, placebo-controlled, clinical trial. Phlebology. 26:162–168. 2011. View Article : Google Scholar : PubMed/NCBI
12	Hall JF: Modern management of hemorrhoidal disease. Gastroenterol Clin North Am. 42:759–772. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zhang X: Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI-1. Exp Ther Med. 5:295–299. 2013. View Article : Google Scholar : PubMed/NCBI
14	Jafarey M, Ashtiyani S Changizi and Najafi H: Calcium dobesilate for prevention of gentamicin-induced nephrotoxicity in rats. Iran J Kidney Dis. 8:46–52. 2014.PubMed/NCBI
15	Pan SL, Guh JH, Huang YW, Chern JW, Chou JY and Teng CM: Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol. 169:724–729. 2003. View Article : Google Scholar : PubMed/NCBI
16	Irwin DC, van Patot MC Tissot, Tucker A and Bowen R: Direct ANP inhibition of hypoxia-induced inflammatory pathways in pulmonary microvascular and macrovascular endothelial monolayers. Am J Physiol Lung Cell Mol Physiol. 288:L849–L859. 2005. View Article : Google Scholar : PubMed/NCBI
17	Demirtas S, Caliskan A, Guclu O, Yazici S, Karahan O, Yavuz C and Mavitas B: Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis? Med Sci Monit Basic Res. 19:253–257. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zhang X, Liu W, Wu S, Jin J, Li W and Wang N: Calcium dobesilate for diabetic retinopathy: A systematic review and meta-analysis. Sci China Life Sci. 58:101–107. 2015. View Article : Google Scholar : PubMed/NCBI
19	Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL and Knowler WC: Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care. 26:76–81. 2003. View Article : Google Scholar : PubMed/NCBI
20	Seyer-Hansen K: Renal hypertrophy in experimental diabetes mellitus. Kidney Int. 23:643–646. 1983. View Article : Google Scholar : PubMed/NCBI
21	Seyer-Hansen K: Renal hypertrophy in streptozotocin-diabetic rats. Clin Sci Mol Med. 51:551–555. 1976.PubMed/NCBI
22	Nyengaard JR and Rasch R: The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia. 36:189–194. 1993. View Article : Google Scholar : PubMed/NCBI
23	Osterby R and Nyberg G: New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications. 1:122–127. 1987. View Article : Google Scholar : PubMed/NCBI
24	Wehner H and Nelischer G: Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats. Virchows Arch A Pathol Anat Histopathol. 419:231–235. 1991. View Article : Google Scholar : PubMed/NCBI
25	Nakagawa T, Kosugi T, Haneda M, Rivard CJ and Long DA: Abnormal angiogenesis in diabetic nephropathy. Diabetes. 58:1471–1478. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H and Watanabe T: Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis. 45:288–294. 2005. View Article : Google Scholar : PubMed/NCBI
27	Min W and Yamanaka N: Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy. Virchows Arch A Pathol Anat Histopathol. 423:201–207. 1993. View Article : Google Scholar : PubMed/NCBI
28	Yuan J, Fang W, Lin A, Ni Z and Qian J: Angiopoietin-2/Tie2 signaling involved in TNF-α induced peritoneal angiogenesis. Int J Artif Organs. 35:655–662. 2012.PubMed/NCBI
29	Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ and Gilbert RE: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 48:2229–2239. 1999. View Article : Google Scholar : PubMed/NCBI
30	Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA and Hugo CP: Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 69:1654–1661. 2006. View Article : Google Scholar : PubMed/NCBI
31	Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E and Bruijn JA: Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis. 43:636–650. 2004. View Article : Google Scholar : PubMed/NCBI
32	Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, Van der Woude FJ, Waldherr R, Rabelink TJ, de Heer E and Bruijn JA: Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 71:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
33	Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, et al: Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 18:1765–1776. 2007. View Article : Google Scholar : PubMed/NCBI
34	García-García PM, Getino-Melián MA, Domínguez-Pimentel V and Navarro-González JF: Inflammation in diabetic kidney disease. World J Diabetes. 5:431–443. 2014. View Article : Google Scholar : PubMed/NCBI
35	Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 27:813–823. 2004. View Article : Google Scholar : PubMed/NCBI
36	Navarro JF, Milena FJ, Mora C, León C and García J: Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol. 26:562–570. 2006. View Article : Google Scholar : PubMed/NCBI
37	Sekizuka K, Tomino Y, Sei C, Kurusu A, Tashiro K, Yamaguchi Y, Kodera S, Hishiki T, Shirato I and Koide H: Detection of serum IL-6 in patients with diabetic nephropathy. Nephron. 68:284–285. 1994. View Article : Google Scholar : PubMed/NCBI
38	Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M and Hada T: Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism. 52:605–608. 2003. View Article : Google Scholar : PubMed/NCBI
39	Navarro JF, Mora C, Muros M and García J: Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant. 21:3428–3434. 2006. View Article : Google Scholar : PubMed/NCBI
40	Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S and Freeman BA: Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol. 257:L399–L410. 1989.PubMed/NCBI
41	Navarro-González JF and Mora-Fernández C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 19:433–442. 2008. View Article : Google Scholar : PubMed/NCBI
42	Vestra M Dalla, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, Plebani M and Fioretto P: Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 16 Suppl 1:S78–S82. 2005. View Article : Google Scholar : PubMed/NCBI
43	Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel RB and Coleman DL: Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int. 38:249–257. 1990. View Article : Google Scholar : PubMed/NCBI
44	Mariño E and Cardier JE: Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD95). Cytokine. 22:142–148. 2003. View Article : Google Scholar : PubMed/NCBI
45	Stuyt RJ, Netea MG, Geijtenbeek TB, Kullberg BJ, Dinarello CA and van der Meer JW: Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology. 110:329–334. 2003. View Article : Google Scholar : PubMed/NCBI
46	Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P and Remuzzi G: Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol. 134:419–430. 1989.PubMed/NCBI
47	DiPetrillo K, Coutermarsh B and Gesek FA: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol. 284:F113–F121. 2003. View Article : Google Scholar : PubMed/NCBI
48	Dipetrillo K and Gesek FA: Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol. 24:352–359. 2004. View Article : Google Scholar : PubMed/NCBI